Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acorda Therapeutics has obtained additional US patent for ampyra covering a range of dosage strengths.
Subscribe to our email newsletter
Ampyra, referred to as fampridine in some countries outside the US, is indicated for the treatment to improve walking in patients with multiple sclerosis (MS) in the US.
The patent covers methods of improving lower extremity function and walking and increasing walking speed in MS patients by administering less than 15mg of sustained release 4-aminopyridine (dalfampridine) twice a day.
The patent eligible for listing in the FDA Orange Book is set to expire in 2025.